Business Description
Invex Therapeutics Ltd
ISIN : AU0000048621
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -25 | |||||
3-Year EPS without NRI Growth Rate | -21.1 | |||||
3-Year FCF Growth Rate | -46.4 | |||||
3-Year Book Growth Rate | -7.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 13.01 | |||||
9-Day RSI | 28.17 | |||||
14-Day RSI | 36.71 | |||||
6-1 Month Momentum % | -57.5 | |||||
12-1 Month Momentum % | -81.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.38 | |||||
Quick Ratio | 6.38 | |||||
Cash Ratio | 6.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 232.88 | |||||
Forward Dividend Yield % | 232.88 | |||||
5-Year Yield-on-Cost % | 227.2 | |||||
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | 454.38 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.17 | |||||
Price-to-Tangible-Book | 1.14 | |||||
Price-to-Net-Current-Asset-Value | 1.14 | |||||
Price-to-Net-Cash | 1.14 | |||||
FCF Yield % | -87.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Invex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.08 | ||
Beta | 1.12 | ||
Volatility % | 61.54 | ||
14-Day RSI | 36.71 | ||
14-Day ATR (A$) | 0.001902 | ||
20-Day SMA (A$) | 0.0855 | ||
12-1 Month Momentum % | -81.72 | ||
52-Week Range (A$) | 0.06 - 0.63 | ||
Shares Outstanding (Mil) | 75.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Invex Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Invex Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Invex Therapeutics Ltd Frequently Asked Questions
What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |